{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:48:23Z","timestamp":1777999703016,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is a rare neuromuscular disease with a rapidly evolving treatment landscape. To better meet the needs of trial sponsors and the patient community in the United States (US) in this evolving context, Cure SMA established a clinical trial readiness program for new and prospective SMA clinical trial sites. Program development was informed by a review of the SMA clinical trial landscape, successful NMD trial and care networks, and factors important to effective trial conduct in SMA. The program was piloted in 2018 with a virtual site readiness evaluation, a trial readiness toolkit, and a readiness program for physical therapists and clinical evaluators. Nine US research hospitals participated in the pilot. Cure SMA evaluated the pilot program and resources through feedback surveys, which supported the program\u2019s relevance and value. Since 2018, the program has been expanded with additional sites, new best practices toolkits, and workshops. In partnership with Cure SMA, SMA Europe is also extending programming to European countries. The program is significant as an example of a patient advocacy group working successfully with pharmaceutical companies, other patient advocacy organizations, and research hospitals to promote trial readiness, and may serve as a model for organizations in other regions and diseases.<\/jats:p>","DOI":"10.1186\/s13023-020-01387-8","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T17:02:41Z","timestamp":1590166961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States"],"prefix":"10.1186","volume":"15","author":[{"given":"Ilse","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-387X","authenticated-orcid":false,"given":"Ros\u00e1ngel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatou","family":"Sarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"publisher","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Rohlfs EM, Flynn K, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72\u2009400 specimens. Eur J Hum Genet. 2012. https:\/\/doi.org\/10.1038\/ejhg.2011.134.","DOI":"10.1038\/ejhg.2011.134"},{"key":"1387_CR2","doi-asserted-by":"publisher","unstructured":"Verhaart IE, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","DOI":"10.1186\/s13023-017-0671-8"},{"key":"1387_CR3","doi-asserted-by":"publisher","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"1387_CR4","doi-asserted-by":"publisher","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995. https:\/\/doi.org\/10.1001\/archneur.1995.00540290108025.","DOI":"10.1001\/archneur.1995.00540290108025"},{"key":"1387_CR5","doi-asserted-by":"publisher","unstructured":"d\u2019Ydewalle C, Sumner CJ. Spinal muscular atrophy therapeutics: where do we stand? Neurotherapeutics. 2015. https:\/\/doi.org\/10.1007\/s13311-015-0337-y.","DOI":"10.1007\/s13311-015-0337-y"},{"key":"1387_CR6","doi-asserted-by":"publisher","unstructured":"Kolb S, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"1387_CR7","doi-asserted-by":"publisher","unstructured":"Barois A, Mayer M, Desguerre I, Chabrol B, Berard C, Cuisset JM, et al. Amyotrophie spinale infantile. Etude multicentrique prospective et longitudinale de 168 cas suivis 4 ans [spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases)]. Bull Acad Natl Med. 2005. https:\/\/doi.org\/10.1016\/S0001-4079(19)33482-X.","DOI":"10.1016\/S0001-4079(19)33482-X"},{"key":"1387_CR8","doi-asserted-by":"publisher","unstructured":"Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Schoneborn S, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999. https:\/\/doi.org\/10.1086\/302369.","DOI":"10.1086\/302369"},{"key":"1387_CR9","doi-asserted-by":"publisher","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, et al. An observational study of functional abilities in infants, children, and adults with type I SMA. Neurology. 2018. https:\/\/doi.org\/10.1212\/WNL.0000000000006050.","DOI":"10.1212\/WNL.0000000000006050"},{"key":"1387_CR10","doi-asserted-by":"publisher","unstructured":"Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry. 2017. https:\/\/doi.org\/10.1136\/jnnp-2016-314292.","DOI":"10.1136\/jnnp-2016-314292"},{"key":"1387_CR11","doi-asserted-by":"publisher","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"1387_CR12","doi-asserted-by":"publisher","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004.","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"1387_CR13","unstructured":"Prior TW, Finange E. Spinal muscular atrophy. In: GeneReviews. 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1116\/. Updated 2016."},{"key":"1387_CR14","doi-asserted-by":"publisher","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0201004.","DOI":"10.1371\/journal.pone.0201004"},{"key":"1387_CR15","doi-asserted-by":"publisher","unstructured":"Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008. https:\/\/doi.org\/10.1007\/s00415-008-0929-0.","DOI":"10.1007\/s00415-008-0929-0"},{"key":"1387_CR16","doi-asserted-by":"publisher","unstructured":"Lefebvre S, Burlet P, Qing L, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997. https:\/\/doi.org\/10.1038\/ng0797-265.","DOI":"10.1038\/ng0797-265"},{"key":"1387_CR17","doi-asserted-by":"publisher","unstructured":"Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018. https:\/\/doi.org\/10.1172\/JCI121658.","DOI":"10.1172\/JCI121658"},{"key":"1387_CR18","doi-asserted-by":"publisher","unstructured":"Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, Kaufmann P. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007. https:\/\/doi.org\/10.1212\/01.wnl.0000290830.40544.b9.","DOI":"10.1212\/01.wnl.0000290830.40544.b9"},{"key":"1387_CR19","doi-asserted-by":"publisher","unstructured":"Rudnik-Sch\u00f6neborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, et al. Genotype\u2013phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01200.x.","DOI":"10.1111\/j.1399-0004.2009.01200.x"},{"key":"1387_CR20","doi-asserted-by":"publisher","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f7e4.","DOI":"10.1212\/WNL.0b013e318271f7e4"},{"key":"1387_CR21","doi-asserted-by":"publisher","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017. https:\/\/doi.org\/10.1002\/ana.25101.","DOI":"10.1002\/ana.25101"},{"key":"1387_CR22","doi-asserted-by":"publisher","unstructured":"Passon N, Dubsky de Wittenau G, Jurman I, Radovic S, Bregant E, Moliniset C, et al. Quick MLPA test for quantification of SMN1 and SMN2 copy numbers. Mol Cell Probes. 2010. https:\/\/doi.org\/10.1016\/j.mcp.2010.07.001.","DOI":"10.1016\/j.mcp.2010.07.001"},{"key":"1387_CR23","doi-asserted-by":"publisher","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007. https:\/\/doi.org\/10.1177\/0883073807305788.","DOI":"10.1177\/0883073807305788"},{"key":"1387_CR24","doi-asserted-by":"publisher","unstructured":"B\u00e9rard C, Payan C, Hodgkinson I, Fermanian J. MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005. https:\/\/doi.org\/10.1016\/j.nmd.2005.03.004.","DOI":"10.1016\/j.nmd.2005.03.004"},{"key":"1387_CR25","doi-asserted-by":"publisher","unstructured":"Montes J, Gordon AM, Pandya S, De Vivo DC, Kaufmann P. Clinical outcome measures in spinal muscular atrophy. J Child Neurol. 2009. https:\/\/doi.org\/10.1177\/0883073809332702.","DOI":"10.1177\/0883073809332702"},{"key":"1387_CR26","doi-asserted-by":"publisher","unstructured":"Mazzone E, Bianco F, Martinelli D, Glanzman AM, Messina S, De Sanctis R, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord. 2011. https:\/\/doi.org\/10.1016\/j.nmd.2011.02.014.","DOI":"10.1016\/j.nmd.2011.02.014"},{"key":"1387_CR27","doi-asserted-by":"publisher","unstructured":"Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurol. 2019. https:\/\/doi.org\/10.1186\/s12883-019-1244-3.","DOI":"10.1186\/s12883-019-1244-3"},{"key":"1387_CR28","doi-asserted-by":"publisher","unstructured":"Bertoli S, Foppiani A, De Amicis R, Leone A, Mastella C, Bassano M, et al. Anthropometric measurement standardization for a multicenter nutrition survey in children with spinal muscular atrophy. Eur J Clin Nutr. 2019. https:\/\/doi.org\/10.1038\/s41430-019-0392-2.","DOI":"10.1038\/s41430-019-0392-2"},{"key":"1387_CR29","doi-asserted-by":"publisher","unstructured":"Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007. https:\/\/doi.org\/10.1177\/0883073807305665.","DOI":"10.1177\/0883073807305665"},{"key":"1387_CR30","doi-asserted-by":"publisher","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017. https:\/\/doi.org\/10.1002\/ana.24864.","DOI":"10.1002\/ana.24864"},{"key":"1387_CR31","unstructured":"U.S. Food and Drug Administration (FDA). News release: FDA approves first drug for spinal muscular atrophy. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm (2016). Accessed 29 May 2019."},{"key":"1387_CR32","unstructured":"U.S. Food and Drug Administration (FDA). News release: FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease (2019). Accessed 29 May 2019."},{"key":"1387_CR33","doi-asserted-by":"publisher","unstructured":"Waldrop MA, Kolb SJ. Current treatment options in neurology-SMA therapeutics. Curr Treat Options Neurol. 2019. https:\/\/doi.org\/10.1007\/s11940-019-0568-z.","DOI":"10.1007\/s11940-019-0568-z"},{"key":"1387_CR34","unstructured":"Cure SMA. SMA drug pipeline. https:\/\/www.curesma.org\/sma-drug-pipeline\/ (2019). Accessed 29 May 2019."},{"key":"1387_CR35","doi-asserted-by":"publisher","unstructured":"Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivio D, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2015. https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8.","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"1387_CR36","unstructured":"U.S. Food and Drug Administration (FDA). Externally-led patient focused drug development meetings. https:\/\/www.fda.gov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/ucm453856.htm. Accessed 29 May 2019."},{"key":"1387_CR37","doi-asserted-by":"publisher","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh W. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017. https:\/\/doi.org\/10.1186\/s12883-017-0853-y.","DOI":"10.1186\/s12883-017-0853-y"},{"key":"1387_CR38","doi-asserted-by":"publisher","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.018.","DOI":"10.1016\/j.nmd.2017.01.018"},{"key":"1387_CR39","unstructured":"Cruz R, Lenz M, Belter L, Hobby K, Jarecki J. Voice of the patient report: A summary report from an externally led patient focused drug development meeting reflecting the U.S. Food and Drug Administration (FDA) patient-focused drug development initiative. 2018. http:\/\/www.curesma.org\/documents\/advocacy-documents\/sma-voice-of-the-patient.pdf. Accessed 29 May 2019."},{"key":"1387_CR40","doi-asserted-by":"publisher","unstructured":"Hunter M, Heatwole C, Luebbe E, Johnson NE. What matters most: a perspective from adult spinal muscular atrophy patients. Neuromuscul Disord. 2018. https:\/\/doi.org\/10.3233\/JND-160168.","DOI":"10.3233\/JND-160168"},{"key":"1387_CR41","doi-asserted-by":"publisher","unstructured":"Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decisions in spinal muscular atrophy: a first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019. https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.012.","DOI":"10.1016\/j.clinthera.2019.03.012"},{"key":"1387_CR42","unstructured":"Cure SMA. Cure SMA clinical trial readiness toolkit. Elk Grove Village (IL): Cure SMA; 2018. Available from: https:\/\/www.curesma.org\/clinical-trial-readiness\/. Accessed 2 Feb 2020."},{"key":"1387_CR43","unstructured":"Cure SMA. Best practices for clinical research coordinators in spinal muscular atrophy (SMA). Elk Grove Village (IL): Cure SMA; 2019. Available from: https:\/\/www.curesma.org\/clinical-trial-readiness\/. Accessed 2 Feb 2020."},{"key":"1387_CR44","unstructured":"Cure SMA. Best practices for physical therapists and clinical evaluators in spinal muscular atrophy (SMA). Elk Grove Village (IL): Cure SMA; 2019. Available from: https:\/\/www.curesma.org\/clinical-trial-readiness\/. Accessed 2 Feb 2020."},{"key":"1387_CR45","unstructured":"Cure SMA. Clinical trial readiness. https:\/\/www.curesma.org\/clinical-trial-readiness\/ (2019). Accessed 2 Feb 2020.."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01387-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T23:11:01Z","timestamp":1621638661000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01387-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01387-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JJ and RC are employees of Cure SMA and report grants from The Cure SMA Industry Collaboration which provided funding for this project. ISP, AMS, and FHS are employees of Faegre Drinker Biddle & Reath LLP. They report paid professional fees to Faegre Drinker Biddle & Reath LLP for their involvement in the design, conduct, and analysis of the work described herein, but did not receive payment for authorship of this manuscript. The support received to conduct this study was noted and it does not result in a conflict of interest for any of the authors. The authors have indicated that they have no other conflicts of interest regarding the content of this article. None of the authors has financial stake in any SMA drug or company involved in developing SMA drugs. Study PI (Dr. Jarecki) did not receive any honoraria or consultancies from industry for her involvement in this study. Study sponsor did not participate in study design, collection, data analysis and interpretation of data or writing of the manuscript. It was the decision of Cure SMA to submit this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}